Loading...

The Treatment of Hormone-Refractory Prostate Cancer: Docetaxel and Beyond

Two randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of meta...

Full description

Saved in:
Bibliographic Details
Main Author: Petrylak, Daniel P
Format: Artigo
Language:Inglês
Published: MedReviews, LLC 2006
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1578715/
https://ncbi.nlm.nih.gov/pubmed/17021642
Tags: Add Tag
No Tags, Be the first to tag this record!